Cerus Corporation
CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Sysā¦ read more
Healthcare
Medical Devices
28 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.71
Price+21.28%
$0.30
1Y
Price
Market Cap
$328.253m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-6.0%
EBITDA Margin-10.9%
Net Profit Margin-5.6%
Free Cash Flow MarginRevenue
$192.510m
+6.8%
1y CAGR+6.2%
3y CAGR+10.6%
5y CAGREarnings
-$18.879m
+9.8%
1y CAGR+22.1%
3y CAGR+21.9%
5y CAGREPS
-$0.10
+9.1%
1y CAGR+23.1%
3y CAGR+23.6%
5y CAGRBook Value
$56.170m
$213.071m
Assets$156.901m
Liabilities$98.898m
DebtDebt to Assets
46.4%
-11.5x
Debt to EBITDAFree Cash Flow
$3.423m
-59.8%
1y CAGR-5.0%
3y CAGR+1.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company